Montu has been ranked number one in LinkedIn Australia’s Top Startups list for 2024 after placing fifth in 2023.
Published each year, the list names 20 emerging Australian companies that “aren’t just growing fast and garnering attention from investors and jobseekers – they’re also building innovative solutions that are shaping the future of their industries”.
The list is built on LinkedIn data across four key pillars: employee growth; jobseeker interest; engagement within the company and its employees; and how well the startups have pulled talent from top companies.
To be eligible, firms must be headquartered in Australia, be fully independent and privately held, have 30 or more full-time employees and be five years old or younger.
Managing director Christopher Strauch said: “It’s an honour to once again be listed among the best companies in Australia. Continuing to attract top-tier talent means we can focus on putting our patients first.”
Australian Natural Therapeutics Group
Australian Natural Therapeutics Group (ANTG) has been named as a finalist in the Regional Exporter category for the 2024 Premier’s NSW Export Awards.
The company was one of the first Australian firms to send medicinal cannabis overseas – with a shipment to Germany in 2020 – and has since expanded its export operation, with the renewal earlier this year of an agreement with Cannamedical valued at A$100 million.
ANTG founder and CEO Matt Cantelo said: “This recognition by the Export Council of Australia is a pleasant surprise for the company. We are already on track to surpass last financial year’s full export tonnage by late 2024.”
ANTG will line up against five other finalists at Sydney Town Hall on October 11.
ECS Botanics
ECS Botanics has appointed Nicholas Thomas as its new chief operating officer while Dr Rachel Swift is joining the board as a non-executive director.
Thomas will oversee the firm’s daily operations, optimise efficiencies, and drive initiatives to support its international expansion and the introduction of B2C product lines.
ECS told the ASX he has “a proven track record in scaling operations and driving commercial improvements across multimillion-dollar B2B and B2C companies”.
He also has extensive experience in agricultural compliance and auditing quality systems, including Good Manufacturing Practice (GMP), the Harmonised Australian Retailer Produce Scheme (HARPS) and the Safe Quality Food Institute (SQFI).
Dr Swift has held senior positions in companies at the forefront of health system management, public health, infectious diseases, digital health, and medical research, including a decade at The Boston Consulting Group where she focused on business strategy, healthcare innovation, and enhancing patient outcomes.
Tilray Medical
Tilray Medical is launching its Redecan EU GMP-certified medical cannabis products in Australia.
Tilray Brands chief strategy officer and head of international Denise Faltischek said the launch of the premium brand “further expands our medical cannabis portfolio alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions”.
Tilray Medical Australia director Jonathan Trodden added: “We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.”